Alzamend Neuro Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALZN research report →
Price Chart
About the company
Alzamend Neuro, Inc. , a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
- CEO
- Stephan Jackman
- IPO
- 2021
- Employees
- 6
- HQ
- Atlanta, GA, US
Get TickerSpark's AI analysis on ALZN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.74M
- P/E
- -0.44
- Fwd P/E
- 0.11
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.79
- EV/EBITDA
- 0.30
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -277.88%
- ROIC
- -156.69%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-8,766,841
- Net Income
- $-8,772,382-94.3%
- EPS
- $-2.63+76.8%
- OCF Growth
- -22.8%
- FCF Growth
- -17.5%
- 52W High
- $2.54
- 52W Low
- $0.75
- 50D MA
- $1.42
- 200D MA
- $1.41
- Beta
- 0.19
- RSI (14)
- 22
- Avg Volume
- 70.27K
No earnings-call transcripts are available for ALZN yet.
- Free Float
- 99.8%
- Shares Outstanding
- 4.83M
- Float Shares
- 4.81M
of shares held by institutions
13 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 21.62K | 0 |
Held by 5 ETFs
Biggest fund positions in ALZN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 26 | AULT MILTON C III | sell | 2,000 |
| Apr 14, 26 | AULT MILTON C III | buy | 2,000 |
| Apr 14, 26 | AULT MILTON C III | buy | 108,388 |
| Apr 14, 26 | AULT MILTON C III | buy | 2,000 |
| Jul 31, 26 | Hyperscale Data, Inc. | other | 7,500 |
| Aug 1, 24 | Hyperscale Data, Inc. | other | 0 |
| Sep 27, 24 | Hyperscale Data, Inc. | other | 0 |
| Oct 30, 24 | Hyperscale Data, Inc. | other | 0 |
| Jul 31, 26 | Hyperscale Data, Inc. | other | 7,500 |
| Aug 1, 24 | Hyperscale Data, Inc. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALZN coverage
Recent articles, reports, and earnings notes.
No research on ALZN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALZN report →Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Oct 8
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
prnewswire.com · Aug 20
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
prnewswire.com · Aug 18
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
prnewswire.com · Aug 4
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
prnewswire.com · Apr 7
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
prnewswire.com · Mar 26
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
prnewswire.com · Mar 16
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?
defenseworld.net · Jan 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.